A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination * Women not of child-bearing potential * Menopausal women * Have a body mass index of 18.0 to 29.0 kilograms per square meter (kg/m\^2) Exclusion Criteria: * Women who are lactating * Have previously completed or withdrawn from this study or any other study investigating baricitinib * Currently enrolled in, have completed or discontinued within the last 90 days from a clinical trial involving an investigational product * Have a pulse rate less than 50 beats per minute (bpm) at screening * Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to Day -1) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection * Have an absolute neutrophil count less than 2000 cells/microliter (2×10\^9/liter) at screening or Day -1 * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine * Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study * Have used or intend to use any drugs or substances that are known to be substrates, inducers, or inhibitors of P-glycoprotein (P-gp) within 30 days prior to dosing and throughout the study * Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose